|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
2782.00
|
|
|
52-Week-Low (Rs.)
|
1599.00
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | 15,770.20 | 14,662.10 | 13,661.10 | 11,167.70 | 9,351.20 | Adjustment | 9,904.90 | 8,279.10 | 8,848.00 | 8,570.80 | 8,207.80 | Changes In working Capital | -296.40 | 862.50 | -4,681.20 | -1,872.50 | -3,158.90 | Cash Flow after changes in Working Capital | 25,378.70 | 23,803.70 | 17,827.90 | 17,866.00 | 14,400.10 | Cash Flow from Operating Activities | 22,654.10 | 21,401.00 | 15,728.90 | 15,799.00 | 12,318.30 | Cash Flow from Investing Activities | -23,840.70 | -1,597.00 | -3,162.80 | 2,694.30 | -3,733.30 | Cash Flow from Financing Activities | 807.40 | -19,772.70 | -15,812.00 | -15,554.80 | -9,275.80 | Net Cash Inflow / Outflow | -379.20 | 31.30 | -3,245.90 | 2,938.50 | -690.80 | Opening Cash & Cash Equivalents | 650.00 | 618.70 | 3,864.60 | 926.10 | 5,129.90 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 583.20 | 0 | 0 | 0 | 0 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | 0 | 0 | 0 | 0 | 0 | Closing Cash & Cash Equivalent | 854.00 | 650.00 | 618.70 | 3,864.60 | 4,439.10 |
|
|
|
|
|
|